Superluminal Medicines logo

Superluminal Medicines

Superluminal Medicines is a Boston biotechnology company that combines structural biology and machine learning to design small molecule drugs for G protein-coupled receptors.

ShareLink copied

The record

Vertical
Pharma & Drug Discovery
Sub-segment
AI and structure based small molecule discovery for GPCRs
Product type
Therapeutics
Stage
Series B
Headquarters
Boston, Massachusetts
Region
North America
Founded
2022

What they do

Superluminal's Hyperloop platform pairs cryo-electron microscopy, which produces many experimental receptor structures, with computational models for docking, molecule design, and predicting absorption and toxicity. The company focuses on endocrine and cardiometabolic diseases. Its lead program is a selective, biased MC4R agonist for rare genetic forms of obesity, such as Bardet-Biedl syndrome, and hypothalamic obesity, with a Phase 1 trial planned to start by the end of 2026. Superluminal also works with Eli Lilly on GPCR targets for cardiometabolic disease and obesity. In September 2026 it closed a $60 million Series B led by BVF Partners.

Leadership & founders

Leadership as of 14 November 2026.

Investors

Related companies

Your daily HealthTech Signal

No hype. Just signal.

Get the latest HealthTech news, understand why it matters, and see where the industry is headed.

5-minute read Delivered daily Unsubscribe anytime

Read by teams at companies like:

Mayo Clinic logoMayo ClinicCleveland Clinic logoCleveland ClinicJohns Hopkins logoJohns HopkinsKaiser Permanente logoKaiser PermanenteEpic logoEpicPhilips logoPhilipsMedtronic logoMedtronicGE HealthCare logoGE HealthCare

Is this your company? Get a Verified profile